Vault-13

Foresite Capital Management VI LLC

WEST HOLLYWOOD, CA · CIK 2013341 · 13F filing filed 2026-05-15

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$460.3m reported value +39.1% vs Q4 2025
17positions
90.5%in top 10
8 new 4 added 1 reduced 3 sold out vs Q4 2025

Holdings, Q1 2026

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 CG ONCOLOGY INC COM CGON CGON 2,221,474 $150.3m32.67% 32.67% UnchangedShares held: Q2 2025 2.2m, Q3 2025 2.2m, Q4 2025 2.2m, Q1 2026 2.2m
2 ALUMIS INC COM ALMS ALMS 4,247,670 $93.6m20.33% 20.33% UnchangedShares held: Q2 2025 4.2m, Q3 2025 4.2m, Q4 2025 4.2m, Q1 2026 4.2m
3 CENTESSA PHARMACEUTICALS PLC SPONSORED ADS SPONSORED ADS 1,364,019 $54.2m11.77% 11.77% UnchangedShares held: Q2 2025 1.3m, Q3 2025 1.3m, Q4 2025 1.4m, Q1 2026 1.4m
4 CORVUS PHARMACEUTICALS INC COM CRVS CRVS 1,831,233 $26.8m5.82% 5.82% AddedShares held: Q2 2025 1.7m, Q3 2025 1.7m, Q4 2025 1.4m, Q1 2026 1.8m +450.0k +450,000 32.6%
5 DENALI THERAPEUTICS INC COM DNLI DNLI 1,209,971 $23.2m5.05% 5.05% AddedShares held: Q2 2025 0, Q3 2025 1.0m, Q4 2025 1.0m, Q1 2026 1.2m +210.0k +209,971 21.0%
6 AGIOS PHARMACEUTICALS INC COM AGIO AGIO 525,000 $17.8m3.86% 3.86% ReducedShares held: Q2 2025 0, Q3 2025 0, Q4 2025 530.0k, Q1 2026 525.0k -5.0k -5,000 -0.9%
7 VERASTEM INC COM NEW VSTM VSTM 3,146,631 $16.7m3.62% 3.62% AddedShares held: Q2 2025 1.3m, Q3 2025 2.6m, Q4 2025 3.1m, Q1 2026 3.1m +11.5k +11,511 0.4%
8 KYMERA THERAPEUTICS INC COM KYMR KYMR 146,332 $12.2m2.65% 2.65% UnchangedShares held: Q2 2025 146.3k, Q3 2025 146.3k, Q4 2025 146.3k, Q1 2026 146.3k
9 MINERVA NEUROSCIENCES INC COM NEW NERV NERV 1,986,600 $12.0m2.60% 2.60% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 2.0m
10 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 315,913 $10.0m2.18% 2.18% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 315.9k
11 ATAIBECKLEY INC COM SHS ATAI ATAI 2,750,000 $9.7m2.12% 2.12% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 2.8m
12 HINGE HEALTH INC CL A HNGE HNGE 220,400 $8.5m1.85% 1.85% AddedShares held: Q2 2025 135.0k, Q3 2025 135.0k, Q4 2025 135.0k, Q1 2026 220.4k +85.4k +85,400 63.3%
13 CRINETICS PHARMACEUTICALS IN COM CRNX CRNX 212,010 $7.7m1.67% 1.67% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 212.0k
14 ONKURE THERAPEUTICS INC COM CL A OKUR OKUR 1,445,783 $6.0m1.30% 1.30% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 1.4m
15 JADE BIOSCIENCES INC COM NEW JBIO JBIO 320,000 $4.5m0.98% 0.98% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 320.0k
16 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 315,492 $4.4m0.96% 0.96% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 315.5k
17 ZURA BIO LTD CLASS A ORD SHS ZURA ZURA 450,000 $2.7m0.58% 0.58% NewShares held: Q2 2025 0, Q3 2025 0, Q4 2025 0, Q1 2026 450.0k

Sold out since Q4 2025

SecurityTickerShares held beforeValue then
RAPT THERAPEUTICS INC RAPT RAPT 1,562,500 $52.9m1.6m shares
NATERA INC NTRA NTRA 67,356 $15.4m67.4k shares
ATAI LIFE SCIENCES NV ATAI ATAI 2,750,000 $11.2m2.8m shares

Trades reported as a company insider in Q1 2026

Owning 10% or more of a company, or having someone on its board, makes this manager an insider there: it reports its trades in that company's shares on Form 4 within two business days. Open-market and private purchases and sales only.

DateCompanyTickerTradeShares ValueTheir holding
2026-01-08 ALUMIS INC 10% owner · See Footnote ALMS Bought 411,764 $7.0m411.8k shares +16%